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Meta-analyses of randomized controlled trials (RTC) have confirmed the
hypocholesterolaemic effect of oats and oat based fibers. However, the mechanisms
by which oats or oat fractions lower cholesterol is not totally clear. Recognizing the
important role of the gut microbiome in metabolism and metabolic disease risk, we
examined the impact of whole grain oat Granola (WGO) on the human gut microbiota and
cardio-metabolic risk factors using a randomized crossover dietary intervention in at risk
individuals (ClinicalTrials.gov Identifier: NCT01925365). We randomized 32 individuals
at risk of developing cardio-metabolic disease by virtue of mild hypercholesterolaemia
or glucose intolerance, into two groups consuming either 45 g of WGO or non-whole
grain (NWG) breakfast cereals daily for two 6-week intervention periods separated by a
4-week wash out period in a randomized, controlled, crossover, double-blinded design.
Confirming the cholesterol lowering effect of WGO, we observed a significant time
by treatment interaction, for total cholesterol (TC) (P = 0.0001) and LDL-cholesterol
(LDL-C) (P = 0.02) compared to NWG. A significant time by treatment interaction
was also observed for the relative abundance of fecal bifidobacteria (P = 0.0001),
lactobacilli (P = 0.001) and total bacterial count (P = 0.008), which were all elevated
after consumption of WGO. Daily consumption of WGO resulted in a prebiotic effect
on the human gut microbiota composition and significant reductions in TC and LDL-C
concentrations. Prebiotic modulation of the human gut microbiota may thus constitute
a previously unrecognized mechanism contributing to the hypocholesterolaemic effects
of whole grain oat Granola.
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INTRODUCTION
Several large epidemiological studies and a number of meta-analyses of nutritional interventions
have reported a positive association between increased whole grain intake and reduced risk of
developing a range of chronic diseases (Chatenoud et al., 1998; Jacobs et al., 1999; Montonen et al.,
2003; Mellen et al., 2008; He et al., 2010; Ye et al., 2012). Consumption of oats or oat based products
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by individuals with various metabolic disease risk factors (e.g.,
hypercholesterolemia, obesity, and diabetes) and in different
ethnic groups, has been shown to mediate an appreciable
normalization of plasma cholesterol levels (Ripsin et al., 1992;
Queenan et al., 2007; Wolever et al., 2011; Charlton et al., 2012;
Zhang et al., 2012). The cholesterol lowering activity of oats is
usually attributed to its ability to reduce intestinal absorption
of cholesterol and/or inhibit the enterohepatic circulation of
bile acids by increasing carriage of cholesterol and/or bile acids
into the colon and facilitating their excretion in feces (Ryan
et al., 2007; Gunness and Gidley, 2010; Borneo and León, 2012).
Whole grain oats contain a number of potentially bioactive
components capable of modulating cholesterol metabolism in
mammals, including unsaturated fatty acids, fibers, such as beta-
glucan, arabinoxylans, arabinogalactans, and resistant starch.
Some of these polysaccharides can form viscous gels in aqueous
solutions, and/or directly bind cholesterol or bile acids, while
all are fermentable by the gut microbiota into short chain
fatty acids (SCFA). Oats, and whole grain oat Granola also
contains polyphenolic compounds and phytoeostrogens which
may also modulate the gut microbiota and impact on host
metabolic parameters (Ryan et al., 2007; Borneo and León,
2012). However, it is the gel forming nature of beta-glucans
which is most commonly attributed to the cholesterol lowering
effect of oats. Tiwari and Cummins (2011) performed a meta-
analysis on 126 studies and concluded that there was a significant
dose-dependent inverse relationship between beta-glucan from
oats and barley and blood total cholesterol, LDL-cholesterol,
and triacylglycerol concentrations with 3 g/day being sufficient
to lower blood total cholesterol by −0.30mmol/L (Tiwari and
Cummins, 2011). While the ability of oats and beta-glucans to
increase excretion of bile acids and cholesterol in feces appears
to be well established, the underlying mechanism still remains
to be fully elucidated. Although the gel forming nature of beta-
glucans reducing bile acid/cholesterol absorption is the most
commonly proposed mechanism, recent studies with probiotic
microorganisms raise the possibility of bile salt hydrolase (BSH)
activity as another possible mechanism by which oats and
fermentable fibers can lower plasma cholesterol (Gunness and
Gidley, 2010; Ooi et al., 2010; Ejtahed et al., 2011; Jones et al.,
2012a,b). Studies on non-gel forming prebiotic fibers, which
modulate gut bacteria and increase BSH active lactobacilli and
bifidobacteria, support the hypothesis that an increased BSH
activity due to gut bacterial modulation could reduce plasma
cholesterol (Tanaka et al., 1999; Kim et al., 2004). Yet few studies
have examined the impact of whole grain oat based food products
on human gut microbiota and no study to date has measured the
ability of dietary oats to modulate the composition and relative
abundance of commensal bacteria in vivo.
The present study aimed to address this knowledge gap
by determining the effectiveness of a whole grain oat (WGO)
Granola breakfast cereal, compared to a refined breakfast cereal
to beneficially modulate gut microbiota and its metabolic output,
plasma lipids, gut satiety hormones and inflammation markers
in a randomized, controlled, double-blind, crossover dietary
intervention study. It tested the hypothesis that whole grain oat
based cereal can mediate a prebiotic modulation of the human
gut microbiota, particularly increased bifidobacteria abundance
and concomitant reduction of plasma LDL cholesterol.
MATERIALS AND METHODS
Subjects
Men and women (age range 23–64 year), recruited from the
general population, attended the Hugh Sinclair Unit of Human
Nutrition, at the University of Reading in a fasted state for
measurement of height, weight, plasma glucose, total cholesterol
concentrations, and hematology. To qualify for entry into the
study subjects required a BMI of 18–30 kg/m2 and either glucose
intolerance (fasting glucose > 5.5 but < 6.9mmol/L) or mild
to moderate hypercholesterolaemic (total cholesterol > 5.2
but < 7.8mmol/L). Exclusion criteria for the study were as
follows: medical history of heart disease, diabetesmellitus, cancer,
pancreatitis or renal disease, use of lipid lowering drugs, systemic
corticosteroids or drugs for regulating hemostasis, exposure to
any investigational agent < 42 d before the study; presence
of gastrointestinal disorder or use of a drug likely to alter
gastrointestinal motility or nutrient absorption, a history of
substance misuse or alcoholism, a current pregnancy, planned
pregnancy, or given birth in the past 12 months, antibiotic
treatment 6 weeks previous to study start date, an allergy or
intolerance to intervention breakfast cereals components or
smoking. The study was conducted according to the guidelines
laid down in the Declaration of Helsinki and was given a
favorable ethical opinion for conduct by the University of
Reading’s Research Ethics Committee. All participants gave
written informed consent before participation. The study was
registered as a clinical trial on ClinicalTrial.gov (NCT01925365).
Study Design
The dietary intervention study was a randomized, double blind,
controlled, crossover design. Thirty-two volunteers (20 women,
12 men) were recruited onto the study. For a 2-week period prior
to dietary intervention, volunteers followed their habitual diet
but were required not to consume confirmed prebiotics (such
as inulin), probiotics (such as live yogurts or fermented milk
drinks), and whole grain products. The subjects were randomly
allocated into one of two groups using a random number
generator. One group consumed the WGO Granola breakfast
cereal (45 g/day) for 6 weeks, and then after a 4-week washout
period, consumed the NWG breakfast cereal (45 g/day) for 6
weeks. The other group received the breakfast cereals in the
opposite order. During each washout period no breakfast cereal
was consumed. All test materials were packaged, labeled and
randomized by Jordans Cereals (Biggleswade., UK) prior to the
study, neither the investigators nor study subjects were aware of
which cereal was allocated.
Study subjects were asked to keep diaries while ingesting
the breakfast cereals, to record stool frequency and consistency
(constipation, hard, formed, soft, or diarrhea), abdominal pain,
intestinal bloating and flatulence (none, mild, moderate, or
severe) on a daily basis. Any concomitantmedication and adverse
events were recorded. Faecal samples, saliva samples, and 20ml
fasting venous blood samples were collected from each volunteer
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at six time points before and after each treatment and 14 days
after each of the treatment periods (i.e., 0, 42, 56, 70, 112, and 126
days).
Composition of Breakfast Cereals
The nutritional composition ofWGO andNWGbreakfast cereals
were provided by Jordans Cereals (Biggleswade., UK) except
for the β-glucan content which was analyzed by Leatherhead
Food Research (using the Megazyme kit). The energy content
of the WGO and NWG cereals was 417 kcal/100 g and 380
kcal/100 g, respectively. WGO, in the form of Granola breakfast
cereal, comprised mainly of whole grain oats with small amounts
of almond and dried fruit, and contained (per 100 g) 67.8 g
carbohydrates, of which 26.8 g sugars; 8.3 g protein, 12.4 g fat,
6.3 g fiber and 2.9 g β-glucan. NWG, in the form of flaked
corn cereal, contained (per 100 g) 84.4 g carbohydrate, of which
8.8 g sugars; 7.4 g protein, 1.1 g fat, 3.0 g fiber and no detectable
β-glucan.
Culture Independent Enumeration of Fecal
Bacteria
Fecal bacteria enumeration was the primary outcome measure.
Fecal samples were stored in an anaerobic cabinet (10% H2;
10% CO2; 80% N2) for no longer than 2 h prior to processing.
Changes in fecal bacteria populations upon consumption of the
test and control cereals were monitored using 16S rRNA probes
labeled with Cy3 for specific bacterial groups or the nucleic
acid stain DAPI for total bacterial counts and Fluorescence
in situ Hybridisation (FISH). The bacterial groups selected for
enumeration were Bifidobacterium spp., Bacteroides/Prevotella
spp., Lactobacillus/ Enterococcus spp., Clostridium coccoides-
Eubacterium rectale group, Clostridium histolyticum group, and
Atopobium cluster including most Coriobacteriaceae species,
using the specific probes Bif164, Bac303, Lab158, Erec482,
His150, and Ato291, respectively (Langendijk et al., 1995; Manz
et al., 1996; Franks et al., 1998; Harmsen et al., 2000). FISH
was performed essentially as described by Rycroft et al. (2001)
and Daims et al. (2005). Briefly, fecal samples (375µl) fixed
in 4% paraformaldehyde (pH 7.2) overnight at 4◦C were then
centrifuged at 1500 × g for 5min, washed twice with phosphate
buffer saline (PBS 0.1 M, pH 7.0), re-suspended in a mixture
of PBS/99% ethanol (1:1 v/v) and stored at −20◦C for up to 3
months.
For the hybridisations, 20 µl of each sample was pipetted
onto Teflon- and poly-l-lysine-coated, six-well (10mm diameter
each) slides (Tekdon Inc., Myakka City, FL, USA). Slides were
dried at 46◦C for 15min and then submerged in a series of
ethanol solutions (50, 80, and 96%, 3 min each). This process
was used for all samples, except those where the Lab158 probe
was used. Sample slides probed with Lab158 were subjected to
an additional step with 50 µl of lysozyme (1mg/mL in 100 mM
Tris-HCl, pH 8.0) at 37◦C for 15min prior to being submerged
in the ethanol solutions. A probe/hybridization buffer mixture
(5 µl of a 50 ng µl−1 stock of probe plus 45 µl of hybridization
buffer) was applied to the surface of each well. Hybridisations
were performed for 4 h in an ISO20 oven (Grant Boekel). Slides
were stored in the dark at 4◦C (for a maximum of 3 days) until
cells were counted. Slides were enumerated using a Nikon E400
Eclipse microscope fitted with an EPI-fluorescence attachment,
15 randomized views were counted for each sample.
SCFA Analysis
High-performance liquid chromatography (HPLC) was
performed to determine fecal SCFA concentration. Aliquots
(1ml) of 10% (w/v) fecal suspension were centrifuged at 13000 g
for 10min and the supernatant was stored at −20◦C for up
to 3 months. Supernatants were then filtered using 0.2mm
polycarbonate syringe filters (Whatman, Maidstone, Kent, UK)
and injected (20µl) into an HPLC system (Merck, Whitehouse
Station, NJ, USA) equipped with refractive index detection. For
the preparation of the external standard containing the SCFA;
acetic, propionic and butyric acid were added to give a final
concentration of 25mM to HCl (6 M) and HPLC gradient water.
Dilutions of the external standards were prepared and added
to the internal standard (ratio 4:1) to give a final concentration
for the internal standard of 20 mM ethyl butyric acid, and
a final concentration of external standards as 80, 40, 20, 10,
5.0, 1.0, and 0.5 mM. The column used was an ion-exclusion
REZEX-ROA organic acid column (Phenomenex, Inc., Torrance,
CA, USA) maintained at 85◦C. H2SO4 in HPLC-grade H2O
(0.0025mmol/l) was used as the eluent, and the flow rate was
maintained at 0.5ml/min. Quantification of the samples was
obtained through calibration curves of acetic, propionic and
butyric acids.
Blood Samples Collection and Analysis
Blood samples were collected into a 10 ml EDTA tube (BD
vacutainer EDTA tube, BD, Cowley, Oxon., UK) for the analysis
of fasting total cholesterol (TC), HDL-cholesterol (HDL-C),
LDL-cholesterol (LDL-C), triacylglycerol (TAG), CRP, IL-6,
TNF-α, PYY, GLP-1 and insulin concentrations; into a 10ml
fluoride/oxalate tube (BD vacutainer fluoride/oxalate tube) for
the analysis of fasting glucose concentration. These blood
analytes were the secondary outcome measures. Following
collection all blood samples were kept on ice until centrifugation.
Plasma samples were recovered by centrifugation at 1700 g for 10
min, dispensed into 1.5ml microcentrifuge tubes and frozen at
−20◦Cwithin 1 h from collection. Plasma samples were defrosted
and centrifuged for 5 min at 1500 g prior to analysis.
Plasma TAG, glucose, CRP, TC, LDL-C, and HDL-C
concentrations were determined on a Monarch Automatic
Analyzer ILab 600 using enzymatic kits (Instrumentation
Laboratories Ltd, Cheshire, UK). Two quality control samples,
(Wako Control Serum I and II. Alpha Laboratories Ltd,
Eastleigh, Hants., UK), containing known normal and abnormal
concentrations were included at the beginning and end of each
batch analysis. Results were accepted if the quality control values
were within the range specified by the manufacturers.
Determination of plasma insulin (DAKO Diagnostic
Ltd, Cambridgeshire, UK), IL-6 and TNF-α (R&D Systems,
Abingdon, UK), PYY and GLP-1 (Yanaihara Institute Inc.
Shizuoka, Japan), feacal and saliva sIgA (Immundianostik AG,
Bensheim, Germany) calprotectin (NovaTec Immundiagnostica
GmbH, Dietzenbach, Germany) concentrations were performed
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using specific commercial ELISA kits according tomanufacturer’s
instructions. Concentrations of the samples and quality controls
were determined automatically by reading from the standard
curve using MasterPlex (version EX 2010) computer software.
Dietary Analysis
Volunteers were asked on week 5 of each of the intervention
arms to complete a 3-day estimated diet diary (2 week and
one weekend day). The volunteers received both verbal and
written instructions on how to complete the diet diaries. These
were analyzed using Dietplan 6.60 (Forestfield Software Ltd),
to determine the macro and micronutrient content of the
participant’s diets during each intervention period.
Statistical Analysis
Normality testing was carried out to determine if data was
normally distributed and transformed if required. Linear mixed
model analysis of variance was performed for testing effects of
visit, treatment, and visit by treatment interaction. Tukey’s post-
test with 95% confidence was used for multiple comparisons
after a visit by treatment interaction was established. Minitab
16 for Windows was used for all analysis. P < 0.05 was taken
as significant. The sample size of 28 was required to detect 0.5
Log10 change in bifidobacterial counts with power set at 0.9, and
a significance level of 0.05 based on previous prebiotic studies
in healthy volunteers conducted with the same microbiological
techniques investigating whole grain maize (Carvalho-Wells




Of the 32 participants recruited, one individual withdrew before
the start of the study due to antibiotic treatment, and another
withdrew after visit 1 due to personal reasons. Samples from
these individuals were excluded from analysis. Thus, a total of
30 participants were included (women n= 19, men n= 11). The
mean age was 42 years with a range between 19 to 60 years. The
participant’s baseline mean weight was 75.2 kg (SD ± 20.4), BMI
26.4 (± 5.7), were mildly hypercholesterolamic TC 5.4 mmol/L
(± 1.0) or glucose intolerant (glucose 5.6± 0.6 mmol/L).
Dietary Analysis
Nutrient analysis of the diets during the two intervention periods
is shown in Table 1. The nutrient intakes in both intervention
periods were similar except for total fat as % of total food
energy (%E) (P = 0.009) and MUFA (%E) (P = 0.002) which
were higher, and starch (%E) (P = 0.007), which was lower
while participants consumed theWGO compared with the NWG
cereal. These differences broadly reflected compliance to the
intervention foods.
Faecal Bacteria and SCFA Analysis
The data for the fecal SCFA analysis is shown in Table 2. No
significant changes were detected either between visits or groups.
Fluorescence in situ hybridization was used to enumerate the
TABLE 1 | Mean (SEM) of daily macronutrient intake during the WGO and
NWG intervention periodsa.
Daily intake (n = 24) WGO treatment NWG treatment P-value
Mean ± SEM mean ± SEM
Energy, kJ 7904±404 7512±349 0.312
Energy, kcal 1916±78 1787±83 0.301
Fat, %E 34.0±1.1 30.6±1.0 0.009
SFA, %E 11.9±0.5 10.9±0.7 0.162
MUFA, %E 12.5±0.6 10.4±0.5 0.002
PUFA, %E 5.9±0.4 5.5±0.4 0.238
Total TFA, %E 0.7±0.1 0.8±0.1 0.158
Protein, %E 16.4±0.8 17.0±0.8 0.407
Carbohydrate %E 49.8±1.3 52.3±1.2 0.073
Starch, %E 27.1±1.2 31.4±1.4 0.007
Total Sugar, %E 21.2±1.1 18.7±1.4 0.080
NSP, g 14.4±0.7 13.9±0.9 0.615
Total fiber (AOAC method), g 18.8±0.9 18.2±1.1 0.626
aDetermined from estimated 3-day dietary diaries. SFA, saturated fatty acids; MUFA,
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids; TFA, trans fatty acids;
NMES, non-milk extrinsic sugars; NSP, non-starch polysaccharide; AOAC, Association of
Official Analytical Chemists.
main gut bacterial groups (Table 3). Baseline levels of all bacterial
groups were comparable between the two treatments. A time by
treatment interaction for bifidobacteria (P = 0.000; Figure 1A),
lactobacilli (P = 0.001; Figure 1B) and total bacterial population
(P = 0.008; Figure 1C) was observed. After consumption of
WGO for a 6-week period the numbers of bifidobacteria (Log10
bacteria cells/g feces) (P = 0.000), lactobacilli (P = 0.000), and
total bacteria population (P = 0.017) significantly increased
compared to the respective baseline. A significant decrease in
bifidobacteria (P = 0.03) and total bacteria population (P =
0.034) was observed on NWG consumption after the 6-week
feeding time. A significant difference at 6 weeks between
bifidobacteria (P = 0.000) and total population (P = 0.003) size
after WGO and NWG was observed, however they returned to
near baseline levels after the 4-week washout. No significant
changes in the population size of Bacteroides spp., Atopobium
spp., and Clostridium group were observed.
Blood Lipid Parameters
Baseline concentrations of all lipid parameters were comparable
between the two treatments (Table 4). A significant time by
treatment interaction for TC (P = 0.000), and LDL-C (P =
0.002) was observed. After consumption of WGO for a 6-week
period, TC concentrations significantly decreased (P = 0.0016),
in contrast after NWG a significant increase in TC levels was
observed (P = 0.0016; Figure 2A). Plasma LDL-C was seen to
significantly increase (P = 0.0055) after consumption of the
NWG cereal (Figure 2B). A significant difference at 6 weeks
between TC (P = 0.000) and LDL-C (P = 0.009) after WGO
and NWG was observed, however they returned to near baseline
levels after the 4-week washout. No significant changes in HDL-
cholesterol, glucose or TAG concentrations were observed.
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TABLE 2 | Mean (±SEM) concentrations of fecal short chain fatty acids (SCFA) before during and after WGO and NWG treatment arms.
Pre-WGO Post-WGO Wash-WGO Pre-NWG Post-NWG Wash-NWG P-value
SCFA Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Time by treat
Acetate, mM/g 53.7±12.5 67.4±12.9 70.3± 15.2 59.4± 15.9 66.8±19.1 57.2±18.4 0.213
Propionate, mM/g 6.5±2.5 21.5±4.1 19.5± 3.2 21.3± 3.5 24.5±4.9 24.3±5.5 0.572
Butyrate, mM/g 14.6±2.0 18.7±5.2 22.1± 4.5 13.4± 3.1 18.2±5.3 15.7±4.6 1.33
(n = 30), visit 1 represents baseline.
TABLE 3 | Mean (± SEM) fecal bacterial numbers (n = 30) over the trial period.
Pre-WGO Post-WGO Wash-WGO Pre-NWG Post-NWG Wash-NWG P-value
Bacteria Group, log10 cells/g feces Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Time by treat
Bifidobacterium 7.97 ± 0.05a 8.35 ± 0.05ab 8.09 ± 0.05a 8.12 ± 0.05bc 8.00 ± 0.04b 7.93 ± 0.05bc 0.000
Bacteroides and Prevotella 8.97 ± 0.05 8.96 ± 0.05 8.95 ± 0.05 8.96 ± 0.05 8.97 ± 0.05 8.94 ± 0.05 0.990
Lactobacillus 8.12 ± 0.06ab 8.28 ± 0.06abe 8.20 ± 0.05abf 8.20 ± 0.05c 8.14 ± 0.05d 8.02 ± 0.05cdef 0.001
Ruminococcus 8.77 ± 0.06 8.89 ± 0.06 8.83 ± 0.07 8.85 ± 0.06 8.70 ± 0.07 8.67 ± 0.07 0.059
Clostridium histolyticum/perfringens 7.98 ± 0.07 7.92 ± 0.06 7.92 ± 0.06 7.95 ± 0.05 7.98 ± 0.06 7.95 ± 0.07 0.632
Atopobium 8.01 ± 0.06 7.97 ± 0.06 8.00 ± 0.05 8.01 ± 0.06 8.05 ± 0.06 8.09 ± 0.05 0.618
Total Population 9.87 ± 0.03a 9.98 ± 0.04abe 9.85 ± 0.03b 9.98 ± 0.03cd 9.87 ± 0.05c 9.78 ± 0.04de 0.008
Bacterial counts in stool samples as determined by fluorescence in situ hybridisation are shown expressed as mean log10 cells/g feces. WGO, Whole Oat Grain; NWG, Non-Whole
Grain; abcdefAll values in one row with a common letter are significantly different from each other (P < 0.05, Tukey’s post-test).
Insulin Sensitivity/Resistance and Marker
of Inflammation
The homeostasis model for insulin resistance (HOMA IR), as
well as QUICKI (model for insulin sensitivity) was calculated
for both treatments (Table 4). There was no significant effect for
either treatment. However, there was a near significant time by
treatment interaction for fasting glucose (p = 0.066). After the
WGO cereal fasting plasma glucose reduced and was lower at the
end of treatment (week 6) than after the NWG. Biomarkers of
inflammation including; C-Reactive Protein (CRP), IL-6, TNF-
alpha from blood plasma, IgA in stool and saliva and calprotectin
levels in stool samples are shown in Table 4. No significant
time by treatment interaction was recorded for any of the
inflammation biomarkers after consumption of either cereal
treatments.
Anthropometric Measures and Satiety Gut
Hormones
The data for changes in volunteer’s GLP-1 and PYY
concentrations and BMI, weight and fat mass are shown in
Table 4. No significant changes were detected between visits or
groups for either of the cereal treatments.
Biomarkers of Gut Health
Stool frequency and consistency, qualitatively graded by
volunteers as hard, formed, or soft, varied considerably between
individuals. No significance differences were observed between
treatments. The severity and frequency of reported changes
in digestive tolerance varied greatly between volunteers, with
neither treatment resulting in adverse symptomology (data not
shown).
DISCUSSION
This novel study was designed to test the hypothesis that a
whole grain oat based Granola breakfast cereal can mediate a
prebiotic modulation of the human gut microbiota typified by
increased relative abundance of bifidobacteria in particular, and
concomitant reduction of plasma LDL cholesterol. These data
also support a significant body of evidence that ingestion of oats,
and oat derived fractions, most notably, β-glucan, at 3 g/day, is
associated with a significant reduction in blood TC and LDL-C in
hypercholesterolemic groups (EFSA Panel on Dietetic Products,
Nutrition and Allergies (NDA), 2010; Tiwari and Cummins,
2011). Although, the bile acid and possibly cholesterol binding
abilities of β-glucans have been suggested to be responsible for the
hypocholesterolemic effects in vivo, other mechanisms may also
be involved, including those linked to the human gut microbiota
which have not been addressed to date. In this study the WGO
group consumed 1.3 g β-glucan daily, which is under half of the
daily recommendation for significant TC and LDL-C reduction.
However, despite the low β-glucan dose, WGO consumption
resulted in 0.94mmol/l and 0.4mmol/l lower concentrations
of TC and LDL-c , respectively, compared with the NWG
at the end of the 6-week intervention period. These data
suggest that other mechanisms of action, other than β-glucan,
could have contributed to the observed cholesterol reduction.
Similar to β-glucan, other fibers or prebiotics, which do not
form viscous gels within the intestinal tract, have been shown
to lower blood cholesterol, though these prebiotics including
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FIGURE 1 | Mean (± SEM) fecal bacteria changes over the trial period
for both cereal treatments (n = 30). (A) Bifidobacteria, (B) Lactobacilli, and
(C) Total Population in stool samples as determined by fluorescence in situ
hybridization. * Significantly different from baseline (P < 0.05, Tukey’s
post-test).
the fructans, xylooligosaccharides, galactooligosaccharides and
resistant starch have not received the same attention from the
scientific community as β-glucans (Park et al., 2004; Beylot,
2005; Sheu et al., 2008; Vulevic et al., 2013). In parallel, a
number of human feeding studies with well-powered cohorts
of hypercholesteroleamic individuals have demonstrated that
probiotics selected for bile salt hydrolase (BSH) activity lower
plasma cholesterol levels to a similar extent to oats and β-glucan
(Jones et al., 2012a,b). Such observations raise the intriguing
possibility, that along with the viscous gel forming activities
of β-glucan, oats may also possess other biological activities
FIGURE 2 | TC and LDL-C concentrations in fasted blood plasma over
the trial period for both cereal treatments (n = 30). (A) TC and (B)
LDL-C. * Significantly different from baseline (P < 0.05, Tukey’s post-test).
which could contribute to their cholesterol lowering ability; not
least the ability to stimulate bacteria within the gut with BSH
activity thereby increasing bile acid deconjugation, facilitating
bile acid excretion in feces and triggering de novo hepatic
bile acid synthesis from circulating cholesterol. Therefore, the
current study was designed to investigate whether WGOmediate
a prebiotic modulation of the human gut microbiota with
specific increases in bifidobacteria, a group of bacteria with well
recognized BSH activity and whether this was associated with
reducing plasma cholesterol (Tanaka et al., 1999).
Currently few studies, and none containing oats, have
measured the ability of whole grain cereals to modulate
bacterial relative abundance in human feces (Costabile et al.,
2008; Carvalho-Wells et al., 2010). Andersson et al. (2013)
observed gut microbiota modulation in response to a dietary
hypocholesterolic intervention with oats in two strains of
C57BL/6 mice. We have previously shown that different whole
grain cereals, including whole grain oat preparations, have
prebiotic potential in vitro, determined by significant stimulation
of both bifidobacteria and lactobacilli bacteria (Connolly et al.,
2010, 2012). Using the same WGO cereal that induced the
highest modulation in bifidobacteria and lactobacilli bacteria
in vitro and also had the lowest GI (37), we have shown for
the first time in humans that WGO consumption for 6 weeks
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TABLE 4 | Mean (±SEM) fasting concentrations of plasma lipids and lipoprotein concentrations, glucose, insulin, markers of insulin resistance, and
inflammatory markers at baseline, during and following ingestion of WGO and NWG.
Pre-WGO Post-WGO Wash-WGO Pre-NWG Post-NWG Wash-NWG P-value
Biomarker Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Mean ± SEM Time by treat
TC, mmol/L 5.38±0.18 4.86± 0.11∞ 4.99±0.17 5.31± 0.19 5.80± 0.23∞ 5.4±0.24 0.000
HDL, mmol/L 1.46±0.08 1.48± 0.08 1.52±0.08 1.51± 0.08 1.50± 0.08 1.43±0.07 0.158
LDL, mmol/L 3.41±0.92 3.22± 1.14 3.18±1.08 3.31± 0.16 3.62± 0.14∞ 3.51±0.15 0.002
TAG, mmol/L 1.21±0.11 1.13± 0.11 1.06±0.11 1.38± 0.20 1.46± 0.20 1.38±0.20 0.518
Glucose, mmol/L 5.44±0.10 5.33± 0.19 5.33±0.12 5.71± 0.13 5.82± 0.11 5.88±0.12 0.066
Insulin, ulU/mL 8.42±0.92 8.66± 1.13 7.72±1.00 7.91± 1.01 10.23± 1.47 8.95±1.08 0.296
HOMA-IR ∇ 2.17±0.27 2.21± 0.32 2.00±0.31 1.99± 0.27 2.63± 0.39 2.31±0.30 0.259
QUICKI ∇ 0.35±0.01 0.36± 0.01 0.36±0.01 0.36± 0.01 0.35± 0.01 0.35±0.01 0.137
CRP, mg/L 1.69±0.35 2.45± 0.92 1.82±0.47 1.80± 0.47 2.36± 0.49 2.02±0.48 0.934
IgA Saliva, ng/mL 265±27 245± 44 288±45 229± 24 340± 47 299±41 0.208
IgA Stool, ng/mL 157±31 154± 39 156±36 162± 31 173± 42 194±48 0.197
TNF-alpha, pg/mL 20.2±4.0 36.5± 15.7 32.9±10.9 46.3± 26.0 42.2± 14.8 27.4±8.4 0.519
Calprotectin, mg/kg 25.2±8.2 25.9± 9.6 20.0±4.9 24.5± 8.9 27.6± 10.3 24.9±8.4 0.066
IL-6, pg/mL 4.13±1.47 5.88± 178 3.85±2.00 4.09± 1.71 7.16± 3.46 4.85±1.74 0.925
PYY, ng/mL 0.88±0.07 0.79± 0.08 0.93±0.07 0.77± 0.06 0.78± 0.03 0.91±0.06 0.551
GLP-1, ng/mL 1.04±0.04 1.01± 0.06 1.12±0.03 1.01± 0.04 1.02± 0.03 1.08±0.03 0.641
BMI, kg/m2 26.3±1.1 26.1± 1.1 26.2±1.1 26.2± 1.0 26.3± 1.0 26.3±1.0 0.061
Fat Mass, kg 23.0±2.0 22.6± 2.0 22.8±2.0 22.8± 1.9 23.2± 2.0 22.9±1.2 0.059
BMI, fat mass and weight and concentrations of satiety gut hormones GLP-1 and PYY of participants before, after and following washout of both test cereals (n= 30).
∞Significantly different from baseline (P < 0.05, Tukey’s post-test).
∇ Insulin sensitivity calculated using Quantitative Insulin Sensitivity Check Index (QUICKI), and insulin resistance calculated using homeostatic model assessment (HOMA) measured
before and after 42 wk of either WGO or NWG treatment. All values are average of volunteer’s measurements ± SEM, (n=30). All measurements were taken in the morning after the
subjects had fasted for 12 h.
can stimulate a prebiotic modulation of the gut microbiota
selectively increasing fecal bifidobacteria, lactobacilli, and total
bacteria compared to a control treatment (Connolly et al.,
2010, 2012). These bacterial numbers returned to baseline levels
after 4 weeks washout in the group of metabolically at risk
participants. No significant changes in Bacteroides spp., C.
histolyticum/perfringens group, or Atopobium spp. was detected
in the fecal samples collected, as also found in previous studies
with other prebiotics. Furthermore, we observed a significant
reduction in TC and LDL-C concentrations after the WGO
treatment compared with NWG supporting other findings (EFSA
Panel on Dietetic Products, Nutrition and Allergies (NDA), 2010;
Tiwari and Cummins, 2011). Although this was associated with
a significantly higher monounsaturated fatty acid (MUFA) and
lower starch intake in theWGO group, this small absolute change
in macronutrient intake is unlikely to have impacted on the
circulating lipids, based on the predicted changes reported by
Mensink et al. (1% dietary energy exchange of carbohydrate
with MUFA was associated with a non-significant reduction in
total cholesterol of 0.006mmol/l and a significant, but relatively
small reduction in LDL-C of 0.009mmol/l) (Mensink et al.,
2003). A number of well controlled animal and human feeding
studies with strains of bacteria which possess bile salt hydrolase
(BSH) activity, like Bifidobacterium and Lactobacillus spp., have
reported significant reductions in circulating TC and LDL-
C levels to a similar degree as oats, β-glucans and other gel
forming fibers like psylleum (Begley et al., 2006; Ooi et al.,
2010; Ejtahed et al., 2011; Jones et al., 2012a,b). In addition in
vitro fermentation studies have shown that various oat fractions,
including β-glucans can both increase SCFA production and
modulate relative abundance of key gut microbiota bacteria
(Hughes et al., 2008; Kim and White, 2009; Connolly et al.,
2012; Nordlund et al., 2012). The ability of oats and β-glucans
to increase SCFA production by the gut microbiota in vitro
and in animal studies has been shown, while few studies have
examined the ability of oats or β-glucans to increase fermentation
in humans (Nilsson et al., 2008; Turunen et al., 2011). It has
been postulated that possible mechanisms of action of prebiotics
on cholesterol reduction may include physiological actions
of SCFA, particularly propionate, to reduce de novo hepatic
cholesterol synthesis by down regulation of HMGCoA reductase;
increased cholesterol excretion from cholesterol assimilation,
deconjugation of bile acids and cholesterol binding to bacterial
or plant cell walls (Shapiro and Rodwell, 1971; Levrat et al.,
1994).
The mechanisms involved with the observed cholesterol
reduction in the present study are not clear. A possible
limitation of the study was that plasma bile salts and SCFA
were not measured. Although it was observed that fecal
SCFA concentrations were similar between treatments, these
data may not reflect plasma SCFA concentrations and this
mechanism cannot be ruled out. Recent studies have shown
that SCFA induce their own active uptake transporters on the
gut wall, hindering the use of fecal SCFA concentrations as
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an indicator of colonic SCFA production from fermentation
(Borthakur et al., 2012). Further mechanistic studies are
required to examine how prebiotic modulation of the gut
microbiota may be linked to cholesterol metabolism, and
specifically whether a prebiotic type microbiota modulation
increases bile acid deconjugation impacting on bile acid excretion
or signaling within the intestine and at other body sites
specifically in the liver and brain. In summary we have
confirmed that dietary WGO ingestion had an appreciable
impact on the composition of the human gut microbiota, and
significantly reduces plasma TC and LDL-C, a step toward
understanding their gut mediated communication with host
energy metabolism.
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